Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide

Implications for internal radiotherapy with 90Y-DOTATOC

Marta Cremonesi, Mahila Ferrari, Stefania Zoboli, Marco Chinol, Michael G. Stabin, Franco Orsi, Helmut R. Maecke, Eduard Jermann, Christopher Robertson, Maurizio Fiorenza, Giampiero Tosi, Giovanni Paganelli

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-DPhe1-Tyr3-octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with 90Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 μg), labelled with 150-185 MBq of 111In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of > 37 GBq/ μmol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for 111In-DOTATOC in blood was 0.9 ± 0.4 h. The injected activity excreted in the urine in the first 24 h was 73% ± 11%. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2 ± 1.8 h in spleen, 1.7 ± 1.2 h in kidneys, 2.4 ± 1.9 h in liver, 1.5 ± 0.3 h in urinary bladder and 9.4 ± 5.5 h in the remainder of the body: the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for 90Y-DOTATOC would be 7.6 ± 6.3 (spleen), 3.3 ± 2.2 (kidneys), 0.7 ± 0.6 (liver), 2.2 ± 0.3 (bladder), 0.03 ± 0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of 90Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation doses to the spleen and kidneys. Tumour doses were high enough in most cases to make it likely that the disired therapeutic response desired would be obtained.

Original languageEnglish
Pages (from-to)877-886
Number of pages10
JournalEuropean Journal Of Nuclear Medicine
Volume26
Issue number8
DOIs
Publication statusPublished - 1999

Fingerprint

Octreotide
Radiotherapy
Spleen
Kidney
Neoplasms
Liver
Urinary Bladder
Urine
Yttrium
Somatostatin Receptors
Indium
Somatostatin
Photons
Animal Models
Bone Marrow
Tomography
indium-111-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
DOTA-Tyr(3)-90Y-octreotide
Radiation
Therapeutics

Keywords

  • Y/In-DOTATOC
  • Dosimetry
  • Peptides

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide : Implications for internal radiotherapy with 90Y-DOTATOC. / Cremonesi, Marta; Ferrari, Mahila; Zoboli, Stefania; Chinol, Marco; Stabin, Michael G.; Orsi, Franco; Maecke, Helmut R.; Jermann, Eduard; Robertson, Christopher; Fiorenza, Maurizio; Tosi, Giampiero; Paganelli, Giovanni.

In: European Journal Of Nuclear Medicine, Vol. 26, No. 8, 1999, p. 877-886.

Research output: Contribution to journalArticle

Cremonesi, Marta ; Ferrari, Mahila ; Zoboli, Stefania ; Chinol, Marco ; Stabin, Michael G. ; Orsi, Franco ; Maecke, Helmut R. ; Jermann, Eduard ; Robertson, Christopher ; Fiorenza, Maurizio ; Tosi, Giampiero ; Paganelli, Giovanni. / Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide : Implications for internal radiotherapy with 90Y-DOTATOC. In: European Journal Of Nuclear Medicine. 1999 ; Vol. 26, No. 8. pp. 877-886.
@article{1c86322cf6b44b72bd20cad482c85238,
title = "Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: Implications for internal radiotherapy with 90Y-DOTATOC",
abstract = "Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-DPhe1-Tyr3-octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with 90Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 μg), labelled with 150-185 MBq of 111In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of > 37 GBq/ μmol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for 111In-DOTATOC in blood was 0.9 ± 0.4 h. The injected activity excreted in the urine in the first 24 h was 73{\%} ± 11{\%}. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2 ± 1.8 h in spleen, 1.7 ± 1.2 h in kidneys, 2.4 ± 1.9 h in liver, 1.5 ± 0.3 h in urinary bladder and 9.4 ± 5.5 h in the remainder of the body: the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for 90Y-DOTATOC would be 7.6 ± 6.3 (spleen), 3.3 ± 2.2 (kidneys), 0.7 ± 0.6 (liver), 2.2 ± 0.3 (bladder), 0.03 ± 0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of 90Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation doses to the spleen and kidneys. Tumour doses were high enough in most cases to make it likely that the disired therapeutic response desired would be obtained.",
keywords = "Y/In-DOTATOC, Dosimetry, Peptides",
author = "Marta Cremonesi and Mahila Ferrari and Stefania Zoboli and Marco Chinol and Stabin, {Michael G.} and Franco Orsi and Maecke, {Helmut R.} and Eduard Jermann and Christopher Robertson and Maurizio Fiorenza and Giampiero Tosi and Giovanni Paganelli",
year = "1999",
doi = "10.1007/s002590050462",
language = "English",
volume = "26",
pages = "877--886",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Berlin Heidelberg",
number = "8",

}

TY - JOUR

T1 - Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide

T2 - Implications for internal radiotherapy with 90Y-DOTATOC

AU - Cremonesi, Marta

AU - Ferrari, Mahila

AU - Zoboli, Stefania

AU - Chinol, Marco

AU - Stabin, Michael G.

AU - Orsi, Franco

AU - Maecke, Helmut R.

AU - Jermann, Eduard

AU - Robertson, Christopher

AU - Fiorenza, Maurizio

AU - Tosi, Giampiero

AU - Paganelli, Giovanni

PY - 1999

Y1 - 1999

N2 - Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-DPhe1-Tyr3-octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with 90Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 μg), labelled with 150-185 MBq of 111In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of > 37 GBq/ μmol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for 111In-DOTATOC in blood was 0.9 ± 0.4 h. The injected activity excreted in the urine in the first 24 h was 73% ± 11%. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2 ± 1.8 h in spleen, 1.7 ± 1.2 h in kidneys, 2.4 ± 1.9 h in liver, 1.5 ± 0.3 h in urinary bladder and 9.4 ± 5.5 h in the remainder of the body: the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for 90Y-DOTATOC would be 7.6 ± 6.3 (spleen), 3.3 ± 2.2 (kidneys), 0.7 ± 0.6 (liver), 2.2 ± 0.3 (bladder), 0.03 ± 0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of 90Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation doses to the spleen and kidneys. Tumour doses were high enough in most cases to make it likely that the disired therapeutic response desired would be obtained.

AB - Recent advances in receptor-mediated tumour imaging have resulted in the development of a new somatostatin analogue, DOTA-DPhe1-Tyr3-octreotide. This new compound, named DOTATOC, has shown high affinity for somatostatin receptors, ease of labelling and stability with yttrium-90 and favourable biodistribution in animal models. The aim of this work was to evaluate the biodistribution and dosimetry of DOTATOC radiolabelled with indium-111, in anticipation of therapy trials with 90Y-DOTATOC in patients. Eighteen patients were injected with DOTATOC (10 μg), labelled with 150-185 MBq of 111In. Blood and urine samples were collected throughout the duration of the study (0-2 days). Planar and single-photon emission tomography images were acquired at 0.5, 3-4, 24 and 48 h and time-activity curves were obtained for organs and tumours. A compartmental model was used to determine the kinetic parameters for each organ. Dose calculations were performed according to the MIRD formalism. Specific activities of > 37 GBq/ μmol were routinely achieved. Patients showed no acute or delayed adverse reactions. The residence time for 111In-DOTATOC in blood was 0.9 ± 0.4 h. The injected activity excreted in the urine in the first 24 h was 73% ± 11%. The agent localized primarily in spleen, kidneys and liver. The residence times in source organs were: 2.2 ± 1.8 h in spleen, 1.7 ± 1.2 h in kidneys, 2.4 ± 1.9 h in liver, 1.5 ± 0.3 h in urinary bladder and 9.4 ± 5.5 h in the remainder of the body: the mean residence time in tumour was 0.47 h (range: 0.03-6.50 h). Based on our findings, the predicted absorbed doses for 90Y-DOTATOC would be 7.6 ± 6.3 (spleen), 3.3 ± 2.2 (kidneys), 0.7 ± 0.6 (liver), 2.2 ± 0.3 (bladder), 0.03 ± 0.01 (red marrow) and 10.1 (range: 1.4-31.0) (tumour) mGy/MBq. These results indicate that high activities of 90Y-DOTATOC can be administered with low risk of myelotoxicity, although with potentially high radiation doses to the spleen and kidneys. Tumour doses were high enough in most cases to make it likely that the disired therapeutic response desired would be obtained.

KW - Y/In-DOTATOC

KW - Dosimetry

KW - Peptides

UR - http://www.scopus.com/inward/record.url?scp=0032764336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032764336&partnerID=8YFLogxK

U2 - 10.1007/s002590050462

DO - 10.1007/s002590050462

M3 - Article

VL - 26

SP - 877

EP - 886

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 8

ER -